Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

Open access

Abstract

Since the late 1980s, mutations in the RAS genes have been recognized as major oncogenes with a high occurrence rate in human cancers. Such mutations reduce the ability of the small GTPase RAS to hydrolyze GTP, keeping this molecular switch in a constitutively active GTP-bound form that drives, unchecked, oncogenic downstream signaling. One strategy to reduce the levels of active RAS is to target guanine nucleotide exchange factors, which allow RAS to cycle from the inactive GDP-bound state to the active GTP-bound form. Here, we describe the identification of potent and cell-active small-molecule inhibitors which efficiently disrupt the interaction between KRAS and its exchange factor SOS1, a mode of action confirmed by a series of biophysical techniques. The binding sites, mode of action, and selectivity were elucidated using crystal structures of KRAS G12C –SOS1, SOS1, and SOS2. By preventing formation of the KRAS–SOS1 complex, these inhibitors block reloading of KRAS with GTP, leading to antiproliferative activity. The final compound 23 (BAY-293) selectively inhibits the KRAS–SOS1 interaction with an IC 50 of 21 nM and is a valuable chemical probe for future investigations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1812963116

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. KRASG12C–SOS1cat NMR fragment screen. (A) Screening cascade (Top) and example spectra for F1 (Bottom): 1D proton spectrum (blue) and STD-NMR spectrum with KRASG12C–SOS1 complex (Cplx.; red), KRASG12C_C118S (green), and SOS1cat (purple). (B) Cocrystal structure of F1 bound to KRASG12C–SOS1cat. (Top) Overall complex with location of the fragment binding site (yellow box); Inset is the area in the yellow box enlarged, showing hydrogen bonds as thin dashed lines and cation–π interaction as a thick dashed line. (C) SPR assay with immobilized SOS1cat. Green line: KRASG12C_C118S; dotted, dashed, and solid blue lines: KRASG12C_C118S in the presence of 100, 250, and 500 µM F1, respectively; dotted, dashed, and solid black lines: respective addition of 100, 250, and 500 µM F1 alone, showing unspecific binding of F1 to SOS1cat; and red line: buffer. (D) F1 and the SOS-activator R1 increase the interaction between KRASG12C_C118S and SOS1cat. (Top) Assay scheme showing RAS, SOS1, and detection antibodies with fluorescent labels (Tb, terbium). (Bottom) Data points represent mean ± SD (n = 4). Normalization: 100% HTRF signal, DMSO control; 0% HTRF signal, without SOS1cat.
Fig. 1. KRASG12C–SOS1cat NMR fragment screen. (A) Screening cascade (Top) and example spectra for F1 (Bottom): 1D proton spectrum (blue) and STD-NMR spectrum with KRASG12C–SOS1 complex (Cplx.; red), KRASG12C_C118S (green), and SOS1cat (purple). (B) Cocrystal structure of F1 bound to KRASG12C–SOS1cat. (Top) Overall complex with location of the fragment binding site (yellow box); Inset is the area in the yellow box enlarged, showing hydrogen bonds as thin dashed lines and cation–π interaction as a thick dashed line. (C) SPR assay with immobilized SOS1cat. Green line: KRASG12C_C118S; dotted, dashed, and solid blue lines: KRASG12C_C118S in the presence of 100, 250, and 500 µM F1, respectively; dotted, dashed, and solid black lines: respective addition of 100, 250, and 500 µM F1 alone, showing unspecific binding of F1 to SOS1cat; and red line: buffer. (D) F1 and the SOS-activator R1 increase the interaction between KRASG12C_C118S and SOS1cat. (Top) Assay scheme showing RAS, SOS1, and detection antibodies with fluorescent labels (Tb, terbium). (Bottom) Data points represent mean ± SD (n = 4). Normalization: 100% HTRF signal, DMSO control; 0% HTRF signal, without SOS1cat.CC BY-NC-ND · PubMed Central
Fig. 2. Discovery of quinazolines as direct SOS1 inhibitors that disrupt the KRAS–SOS1 complex. (A, Top) Assay schemes (showing KRAS, fluorescently labeled GDP and GTP nucleotides, SOS1, and detection antibodies with fluorescent terbium label), and (A, Bottom) dose–response curves for GDP, compound 1, and KRAS reference compound R2 (SI Appendix, Table S2), shown for the On-assay (Left) and the secondary Off-assay (Middle). Data points represent mean ± SD (n = 4). (B, Left) TSA. Compound 1 stabilizes SOS1cat with a ΔTm of 2.5 °C. (B, Middle, Top) ITC of the interaction of 1 with SOS1cat. (B, Middle, Bottom) Heat curve of titration of SOS1cat into a solution of 1 and integrated enthalpies plotted against the protein-to-compound molar ratio. Inset shows thermodynamic values obtained from fitting a Wiseman isotherm to the measured calorimetric data. (B, Right) Native MS analysis confirmed binding of 1 to SOS1cat with a 1:1 stoichiometry. (C, Left) HTRF-based KRASG12C–SOS1cat interaction assay showing disruption of the KRASG12C–SOS1cat complex by 1 (red curve); the SOS activator R1 (green curve, SI Appendix, Table S2) leads to a stabilization of the KRASG12C–SOS1cat complex. Data points represent mean ± SD (n = 4). Normalization as in Fig. 1D. (C, Right) SPR assay with immobilized SOS1cat. Green: 250 nM KRASG12C_C118S; blue: 250 nM KRASG12C_C118S in the presence of 10 µM compound 1; black: 10 µM 1 alone, showing unspecific binding of 1 to SOS1cat; and red: buffer. Compound 1 resulted in reduced binding of KRASG12C to immobilized SOS1cat.
Fig. 2. Discovery of quinazolines as direct SOS1 inhibitors that disrupt the KRAS–SOS1 complex. (A, Top) Assay schemes (showing KRAS, fluorescently labeled GDP and GTP nucleotides, SOS1, and detection antibodies with fluorescent terbium label), and (A, Bottom) dose–response curves for GDP, compound 1, and KRAS reference compound R2 (SI Appendix, Table S2), shown for the On-assay (Left) and the secondary Off-assay (Middle). Data points represent mean ± SD (n = 4). (B, Left) TSA. Compound 1 stabilizes SOS1cat with a ΔTm of 2.5 °C. (B, Middle, Top) ITC of the interaction of 1 with SOS1cat. (B, Middle, Bottom) Heat curve of titration of SOS1cat into a solution of 1 and integrated enthalpies plotted against the protein-to-compound molar ratio. Inset shows thermodynamic values obtained from fitting a Wiseman isotherm to the measured calorimetric data. (B, Right) Native MS analysis confirmed binding of 1 to SOS1cat with a 1:1 stoichiometry. (C, Left) HTRF-based KRASG12C–SOS1cat interaction assay showing disruption of the KRASG12C–SOS1cat complex by 1 (red curve); the SOS activator R1 (green curve, SI Appendix, Table S2) leads to a stabilization of the KRASG12C–SOS1cat complex. Data points represent mean ± SD (n = 4). Normalization as in Fig. 1D. (C, Right) SPR assay with immobilized SOS1cat. Green: 250 nM KRASG12C_C118S; blue: 250 nM KRASG12C_C118S in the presence of 10 µM compound 1; black: 10 µM 1 alone, showing unspecific binding of 1 to SOS1cat; and red: buffer. Compound 1 resulted in reduced binding of KRASG12C to immobilized SOS1cat.CC BY-NC-ND · PubMed Central
Fig. 3. SOS1–compound 1 cocrystal structure, SAR, and crystal structure of SOS2. (A, Left) Cocrystal structure of SOS1SB (carbon atoms in gray) in complex with 1 (stick model, carbon atoms in green). (B, Left) Crystal structure of SOS1SB in complex with 1 (protein carbon atoms in gray, inhibitor carbon atoms in green), superimposed with the crystal structures of apo SOS1SB (selected binding site residues shown, carbon atoms in yellow) and KRASG12C_SB–SOS1cat (KRAS in orange, SOS1 carbon residues in magenta). Magenta dashed line indicates a stacking interaction between the side chain of Tyr884 and KRAS residue Arg73. Red arrow highlights a predicted clash between one of the two methoxy groups of the inhibitor with Arg73KRAS. (C) Superimposition of the crystal structures of SOS1SB (gray ribbon) in complex with 1 and apo SOS2SB (magenta). Overall view (Left) and Inset view (Right) into the inhibitor binding site. (A, Right and B, Right and D) Initial SAR data for the SOS1 inhibitor series. IC50 values measured with the KRASG12C–SOS1cat interaction assay and EGFR kinase inhibition assay (mean values; see SI Appendix, Table S8 for SD and biological replicates).
Fig. 3. SOS1–compound 1 cocrystal structure, SAR, and crystal structure of SOS2. (A, Left) Cocrystal structure of SOS1SB (carbon atoms in gray) in complex with 1 (stick model, carbon atoms in green). (B, Left) Crystal structure of SOS1SB in complex with 1 (protein carbon atoms in gray, inhibitor carbon atoms in green), superimposed with the crystal structures of apo SOS1SB (selected binding site residues shown, carbon atoms in yellow) and KRASG12C_SB–SOS1cat (KRAS in orange, SOS1 carbon residues in magenta). Magenta dashed line indicates a stacking interaction between the side chain of Tyr884 and KRAS residue Arg73. Red arrow highlights a predicted clash between one of the two methoxy groups of the inhibitor with Arg73KRAS. (C) Superimposition of the crystal structures of SOS1SB (gray ribbon) in complex with 1 and apo SOS2SB (magenta). Overall view (Left) and Inset view (Right) into the inhibitor binding site. (A, Right and B, Right and D) Initial SAR data for the SOS1 inhibitor series. IC50 values measured with the KRASG12C–SOS1cat interaction assay and EGFR kinase inhibition assay (mean values; see SI Appendix, Table S8 for SD and biological replicates).CC BY-NC-ND · PubMed Central
Fig. 4. Structure-based linking of the fragment and HTS hits. (A, Left) Superimposition of the crystal structures of F1 bound to KRASG12C_SB–SOS1cat (KRAS in orange, SOS1 in gray, F1 and Phe890 with carbon atoms in magenta) and 17 bound to SOS1SB (only inhibitor and Phe890 shown; carbon atoms in green). (Right) Schematic depiction of the merging approach, with 18 as an initial example of the resulting hybrid compounds. (B, Left and C, Left) Crystal structures of SOS1SB in complex with 21 (B) and 23 (C); hydrogen bonds shown as thin dashed lines, cation–π interaction as a thick dashed line. (B, Right and C, Right) IC50 values measured with the KRASG12C–SOS1cat interaction assay (mean values; see SI Appendix, Table S8 for SD and biological replicates). (C, Bottom Right) Dose–response curves for compounds 22 to 24.
Fig. 4. Structure-based linking of the fragment and HTS hits. (A, Left) Superimposition of the crystal structures of F1 bound to KRASG12C_SB–SOS1cat (KRAS in orange, SOS1 in gray, F1 and Phe890 with carbon atoms in magenta) and 17 bound to SOS1SB (only inhibitor and Phe890 shown; carbon atoms in green). (Right) Schematic depiction of the merging approach, with 18 as an initial example of the resulting hybrid compounds. (B, Left and C, Left) Crystal structures of SOS1SB in complex with 21 (B) and 23 (C); hydrogen bonds shown as thin dashed lines, cation–π interaction as a thick dashed line. (B, Right and C, Right) IC50 values measured with the KRASG12C–SOS1cat interaction assay (mean values; see SI Appendix, Table S8 for SD and biological replicates). (C, Bottom Right) Dose–response curves for compounds 22 to 24.CC BY-NC-ND · PubMed Central
Fig. 5. Cellular characterization of compounds 22 to 24. (A) Inhibition of active RAS levels in HeLa cells. (B) pERK levels in K-562 cells. (C) Correlation of IC50 data for pERK inhibition in K-562 cells with biochemical KRAS–SOS1 interaction. (D) pERK levels in Calu-1 cells. The colored dots represent compounds 22 (red), 23 (green), and 24 (blue). Reference compounds (SI Appendix, Table S2) in A, B, and D are indicated in gray. Data points in A, B, and D represent mean ± SD (n = 4). The IC50 values of 22 to 24 for these assays are summarized in SI Appendix, Table S6. (E) Antiproliferative activity against wild-type KRAS cell lines (K-562, MOLM-13) and cell lines with KRASG12C mutation (NCI-H358, Calu-1). Mean IC50 values ± SD, n = 4. (F) Antiproliferative activity of 23 (Left) and 24 (Middle) was assessed in combination with the covalent KRASG12C inhibitor ARS-853 in NCI-H358 cells. IC50 isobologram plots of SOS1-inhibitors (Z1) and ARS-853 (Z11) alone and of fixed combinations (Z2 to Z10) of both compounds are shown. The dotted line represents the line of additivity. Data points represent mean ± SD of biological independent experiments (n = 3). (Right) The combination index was calculated according to the median-effect model of Chou–Talalay (43); a value below 0.8 indicates a more-than-additive (i.e., a synergistic) interaction.
Fig. 5. Cellular characterization of compounds 22 to 24. (A) Inhibition of active RAS levels in HeLa cells. (B) pERK levels in K-562 cells. (C) Correlation of IC50 data for pERK inhibition in K-562 cells with biochemical KRAS–SOS1 interaction. (D) pERK levels in Calu-1 cells. The colored dots represent compounds 22 (red), 23 (green), and 24 (blue). Reference compounds (SI Appendix, Table S2) in A, B, and D are indicated in gray. Data points in A, B, and D represent mean ± SD (n = 4). The IC50 values of 22 to 24 for these assays are summarized in SI Appendix, Table S6. (E) Antiproliferative activity against wild-type KRAS cell lines (K-562, MOLM-13) and cell lines with KRASG12C mutation (NCI-H358, Calu-1). Mean IC50 values ± SD, n = 4. (F) Antiproliferative activity of 23 (Left) and 24 (Middle) was assessed in combination with the covalent KRASG12C inhibitor ARS-853 in NCI-H358 cells. IC50 isobologram plots of SOS1-inhibitors (Z1) and ARS-853 (Z11) alone and of fixed combinations (Z2 to Z10) of both compounds are shown. The dotted line represents the line of additivity. Data points represent mean ± SD of biological independent experiments (n = 3). (Right) The combination index was calculated according to the median-effect model of Chou–Talalay (43); a value below 0.8 indicates a more-than-additive (i.e., a synergistic) interaction.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 403

Metadata

Authors
Hillig, R. C., Sautier, B., Schroeder, J., Moosmayer, D., Hilpmann, A., Stegmann, C. M., Werbeck, N. D., Briem, H., Boemer, U., Weiske, J., Badock, V., Mastouri, J., Petersen, K., Siemeister, G., Kahmann, J. D., Wegener, D., Böhnke, N., Eis, K., Graham, K., Wortmann, L., von Nussbaum, F., & Bader, B.
Affiliations
  • Bayer (Germany) (DE)
  • Evotec (Germany) (DE)
  • Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany;
Corresponding author
  • Hillig, Roman C.
  • Bader, Benjamin
Venue
Proceedings of the National Academy of Sciences
Published
2019-01-25
Volume
116
Issue
7
Pages
2551-2560
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2912277053
Cited by
388
References
43
Citations by year
2026: 29 · 2025: 45 · 2024: 67 · 2023: 65 · 2022: 62 · 2021: 61 · 2020: 43 · 2019: 16
FWCI
15.56
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Desy publication database (The Deutsches Elektronen-Synchrotron) (submittedVersion, cc-by-nc-nd)
  • HZB Repository (Helmholtz-Zentrum Berlin für Materialien und Energie GmbH (HZB)) (submittedVersion, other-oa)
  • Repository of Futwangen University of Applied Sciences (Furtwangen University) (submittedVersion, cc-by-nc-nd)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
SOS1 inhibitor, KRAS, Ras activation, guanine nucleotide exchange factor, small molecule inhibitors, KRAS G12C, SOS2, GTP loading, oncogenic Ras mutations, antiproliferative activity, chemical probes
MeSH terms
Cell Line, Humans, Protein Binding, Signal Transduction, Proto-Oncogene Proteins p21(ras), Crystallography, X-Ray, SOS1 Protein, Fluorescence Resonance Energy Transfer, Drug Discovery, High-Throughput Screening Assays

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction. https://app.cochat.ai/papers/10.1073/pnas.1812963116
The paper
Hillig, R. C., Sautier, B., Schroeder, J., Moosmayer, D., Hilpmann, A., Stegmann, C. M., Werbeck, N. D., Briem, H., Boemer, U., Weiske, J., Badock, V., Mastouri, J., Petersen, K., Siemeister, G., Kahmann, J. D., Wegener, D., Böhnke, N., Eis, K., Graham, K., . . . Bader, B. (2019). Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1812963116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.